Apimeds Pharmaceuticals US Enters Assignment And Transfer Agreement With Freet On Aug 19, 2026; Freet Assigns All Apitox-Related Rights To Apimeds Pharmaceuticals; Receives 100% Korean Clinic Rights, 25% U.S. Royalty, 25% Overseas Revenue Participation For Apitox